Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...
Amgen has failed in a legal attempt to block the sale of a biosimilar version of its white blood cell stimulator Neupogen developed by Novartis' Sandoz subsidiary. The biosimilar – called Zarxio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback